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especially miRNA transfection and 
delivery need to be improved. The trans-
fection or delivery of miRNA to target cells 
could efficiently treat various human dis-
eases such as cancers and cardiovascular 
diseases, but has been limited by the low 
membrane permeability and poor serum 
stability of miRNAs.[4–6] Although cati-
onic polymers and liposomes are widely 
investigated as nonviral vectors to over-
come the intrinsic weaknesses of nucleo-
tides, their miRNAs delivery was always 
unsatisfactory due to their cytotoxicity and 
uncontrollability.[7–9] To overcome these 
limitations, it is very necessary to develop 
next generation nonviral vectors with high 
miRNA delivery efficiency, minimal cyto-
toxicity, and smart responsive release.[10]
Theta defensin (θ-defensin), a family 
of arginine-rich humanized antimicrobial 
cyclopeptides with large β-sheet struc-
tures stabilized by disulfide linkages and 
connected by turns, is well known for 
its antivirus and antibacterial activity via 
destabilizing the microprotein by the high 
positive charge density of defensin.[11–13] 
Previous studies have shown that θ-defensin is nontoxic and 
nonimmunogenic in vitro and in vivo, suggesting its great bio-
compatibility.[14–16] θ-defensin can also suppress the produc-
tion of proinflammatory cytokines and modulate the immune 
response, indicating its potential in disease therapy.[17–19] Addi-
tionally, the Arg-Gly-X (RGX) sequence-contained structure 
Synthetic cationic vectors have shown great promise for nonviral gene 
delivery. However, their cytotoxicity and low efficiency impose great restric-
tions on clinic applications. To push through this limitation, humanized 
peptides or proteins with cationic biocompatibility as well as biodegrada-
tion would be an excellent candidate. Herein, for the first time, we describe 
how an arginine-rich humanized antimicrobial cyclopeptide, θ-defensin, 
can be used as a synthetic cationic vector to load and deliver miRNA into 
bone mesenchymal stem cells with high efficiency and ultralow cytotoxicity, 
surpassing the efficiency of the commercial polyethylenimine (25 kD) and 
Lipofectamine 3000. To note, θ-defensin can redox-responsively release the 
loaded miRNA through a structural change: in extracellular oxidative environ-
ment, θ-defensin has large β-sheet structures stabilized by three disulfide 
linkages, and this special structure enables highly efficient delivery of miRNA 
by passing through cell membranes; in intracellular environment, redox-
responsive disulfide linkages are broken and the tight β-sheet structures are 
destroyed, so that the miRNA can be released. Our results suggest that syn-
thetic θ-defensin peptides are a new class of nonviral gene vectors and this 
study may also provide a promising strategy to design smart-responsive gene 
vectors with high efficiency and minimal toxicity.
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MicroRNAs (miRNAs), a class of short noncoding RNAs 
(18–25 nt), play an important role in regulating various bio-
logical processes through modulating post-transcriptional gene 
expression of gene targets, including cell proliferation, differ-
entiation, and apoptosis.[1–3] In biologically relevant cell models 
and cell therapy, the existing molecular and cellular techniques, 
Adv. Biosys. 2017, 1, 1700001
www.adv-biosys.comwww.advancedsciencenews.com
1700001 (2 of 6) © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
in θ-defensin enables the potent binding ability for integrin 
which is highly expressed at the surface of bone mesenchymal 
stem cells (BMSCs).[20] As progenitor cells, BMSCs can differ-
entiate into various tissue cells and have exhibited promising 
applications in tissue regeneration and disease therapy.[21] After 
binding to the integrin of BMSCs and internalization into the 
cells, the reducing cytoplasm breaks the disulfide linkages of 
θ-defensin and reduces its positive charge density.[22] Following 
this, the loaded genes will be redox-responsively released and 
the reducing θ-defensin can be biodegraded into amino acids 
via enzymolysis. These unique properties endow θ-defensin 
with promising potential for highly efficient miRNA delivery.
Herein, for the first time, we present the performance of 
synthetic θ-defensin peptides as highly efficient nonviral vec-
tors for miRNA-5106 (miR-5106) delivery to BMSCs for regu-
lating their osteoblastic differentiation to settle for bone tissue 
engineering application. For embodying the excellent transfec-
tion capacity of θ-defensin, Lipofectamine 3000, the best com-
mercial nonviral vector known as having the most superior 
efficiency and lowest toxicity was chosen to be compared with 
θ-defensin. Meanwhile, PEI 25K, the most common commer-
cial vector for DNA or RNA with reliable outcomes, was used 
as positive control in this work. In a previous study, miR-5106 
was identified from BMSCs and showed a good performance 
to enhance osteoblastic differentiation of BMSCs.[23] A fur-
ther study showed that miR-5106 could significantly enhance 
osteogenic gene expressions (Runx2, Sp7) through targeting 
Gsk3a, which was proved by quantitative real-time polymerase 
chain reaction (qRT-PCR), dual-luciferase vector analysis and 
western blot experiment (Figure S1, Supporting Information). 
The improved osteogenic differentiation by the downregulation 
of Gsk3a was also seen in previous references.[24,25] As shown 
in Scheme 1, the 18-residue θ-defensin peptides (RC101, an 
artificial mutant from the natural Theta-Defensin Retrocyclin) 
including three arginine, a lysine, and three disulfide bond, 
was synthesized by a solid phase peptide synthesis (SPSS) and 
native chemical ligation (NCL). The RC101 with a high positive 
charge density and good cell-penetrating ability could efficiently 
condense miR-5106 and deliver it into cells for regulating 
target gene expressions. In the intracellular reductive environ-
ment, the three disulfide bonds in RC101 would be broken, so 
that dense β-sheet structure broke down and changed to an 
incompact loop. And this structure change of RC101 would 
lead to the decrease of positive charge density, which could 
reduce the adsorption of the electronegative miR-5106 and 
enable the redox-responsive controlled release of miR-5106 
(Scheme 1). After that, miR-5106 may incorporate into RNA 
induced silencing complex (RISC), mediate Gsk3a mRNA 
translational repression, and induce osteogenic regulator gene 
Runx2, and Sp7 expression which could enhance BMSC osteo-
blastic differentiation (Scheme 1).
To validate this concept, a backbone ribbon model of RC101 
and its reduced form, were first made by templating its 
sequence on the structure of protegrin-1 (PG-1), and cyclizing 
it (Figure 1A).[26] The resulting structure was annealed by the 
molecular dynamics as well as energy minimized, and fur-
ther verified by circular dichroism spectrum (Figure 1B). 
These results confirmed the dense β-sheet structure of RC101, 
and this structure can be changed to a flexible loop at the 
reduced form. Moreover, the native and reduced structure of 
RC101 were confirmed by high performance liquid chroma-
tography (HPLC) and electrospray ionization mass spectrom-
etry (ESI-MS), and the increase of molecular weight from 
1890.2 to 1896.4 Da indicated the breaking of three disulfide 
bonds after reduction (Figure 1C,D). The dynamic simulation 
clearly showed that RC101 demonstrated significantly high 
positive charge density compared with the reduced RC101 
(Figure S2, Supporting Information). RC101 possessed a zeta 
potential of 42.3 mV and this value was significantly decreased 
to 0.08 mV after reduction (Figure 1E). These results suggested 
that in extracellular oxidative environment, θ-defensin has 
large β-sheet structures stabilized by three disulfide linkages, 
and this arginine-rich compact structure has the high positive 
charge density to adsorb miRNA; in intracellular environment, 
redox-responsive disulfide linkages were broken and the tight 
β-sheet structures were destroyed, so the positive charge den-
sity sharped fall (reduced RC101) and miRNA can be released. 
The structure of RC101 is well suited for delivering miRNA 
compared to reduced RC101. To validate the effectiveness of 
RC101 in delivering miRNA, we detect the binding ability and 
stability of RC101–miRNA (Figure 1; Figures S3 and S4, Sup-
porting Information). To demonstrate the promising potential 
of RC101 for miRNA delivery, the RC101-mediated miR-5106 
transfection efficiency in BMSCs was evaluated, using com-
mercial transfection reagents PEI 25 K and Lipo as controls 
(Figure 2; Figures S5–S10, Supporting Information) by viability 
test, confocal microscopy, real-time PCR analysis, and von 
Kossa stain.
After incubating with miR-5106, the representative RC101@
miR-5106 and reduced RC101@miR-5106 nanocomplexes 
with a size of 50–70 nm were formed (Figure S3, Supporting 
Information). The gel electrophoresis analysis showed that 
the miR-5106 was efficiently condensed by RC101 at a weight 
ratio of 30:1, which was comparable to PEI 25K (Figure S4A, 
Supporting Information). Due to the strong positive charge 
density, RC101 showed an ≈twofold high miR-5106 loading 
ability compared with the reduced RC101, as well as signifi-
cantly high binding capacity relative to commercial PEI 25K at 
the same mass (Figure 1F). In the presence of polyanion (hep-
arin), RC101 still exhibited almost two times higher miR-5106 
binding stability than PEI 25K, and over 14-fold higher com-
pared with commercial Lipo and reduced RC101 (Figure 1G; 
Figure S4B, Supporting Information). Additionally, the serum 
stability test clearly showed that RC101 completely protected 
miR-5106 against the enzymolysis over 3 h, whereas the 
naked miR-5106 as well as Lipo@ miRNA were completely 
digested during 3 h with a half-life time of 0.26 and 0.27 h, 
respectively (Figure 1H; Figure S4C, Supporting Information). 
These results unequivocally demonstrate that RC101 may be 
an excellent nonviral vector for miRNA delivery, based on its 
high efficient miRNA loading and protecting miRNA against 
serum degradation and redox-responsive controlled release of 
miRNAs.
The cytotoxicity of PEI-based polymers and Lipo is one 
of the main obstacles to limit their successful clinical gene 
therapy applications. Therefore, it is necessary to evaluate the 
cytotoxicity of nonvirial vectors before their applications. Here, 
RC101 with different concentrations (30–240 µg mL−1) showed 
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a significantly high BMSCs viability and negligible cytotoxicity, 
while the commercial liposome transfection reagents Lipo and 
PEI 25K exhibited significant cytotoxicity (Figure 1I; Figure S5, 
Supporting Information). RC101@miR-5106 with different 
weight ratios presented ultralow cytotoxicity at day 1 and could 
enhance the cell proliferation after incubation for 5 d (Figure 1J; 
Figure S6A, Supporting Information). Additionally, BMSC pro-
liferation was significantly improved by RC101 during further 
5 d culture, as compared to PEI 25K and Lipo (Figure S6B, Sup-
porting Information). The ultralow cytotoxicity of RC101 made 
it highly competitive as efficient nonvirus vectors for miRNA 
delivery.
The confocal laser scanning microscope images clearly 
showed that much more miR-5106 was transfected into BMSCs 
compared with PEI 25K and Lipo after incubation for 48 h 
(Figure 2A,B). RC101@miR-5106 transfected cells exhibited 
around three (two) times higher fluorescent intensity than PEI 
25K (Lipo) groups (Figure 2C). The quantitative flow cytometry 
result also confirmed the significantly high miR-5106 transfec-
tion efficiency, as compared to PEI 25K and Lipo (Figure 2B 
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Scheme 1. Schematic illustration of synthesized θ-defensin peptides (RC101) for miRNA delivery. A) Reduced RC101 was synthesized by a solid phase 
peptide synthesis (SPSS) and native chemical ligation (NCL). After the oxidation of disulfide bonds, the miR-5106 can be loaded efficiently on the sur-
face of the oxidative form of reduced RC101; B) RC101 with a high positive charge density and good cell-penetrating ability could efficiently condense 
miR-5106 and deliver it into BMSCs for regulating target gene expressions. In the intracellular reductive environment (GSH), the three disulfide bonds 
in RC101 would be broken, which could reduce the adsorption of the electronegative miR-5106 and enable the redox-responsive controlled release of 
miR-5106. Over-expression of miR-5106 could downregulate Gsk3a expression, which may result in osteogenic differentiation.
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and C). Compared with RC101, the reduced RC101 presented 
a significantly low miR-5106 transfection ability, indicating the 
importance of positive charge density in RC101 (Figure S7, 
Supporting Information). The qRT-PCR analysis normalized by 
the housekeeping gene, GAPDH, further confirmed that signif-
icantly high miR-5106 expression in BMSCs for RC101 group 
was observed after 3 weeks in comparison with PEI 25K and 
Lipo (Figure 2D; Figure S8A, Supporting Information).
Figure 2. Highly efficient miRNA intracellular delivery, transfection, and gene regulation ability of RC101. A) Confocal laser scanning microscopy 
pictures of BMSCs with FAM-labeled miRNA transfected by PEI 25K, Lipo, and RC101 (Scale bar = 100 µm); B) flow cytometry analysis in the transfec-
tion efficiency of FITC labeled miRNA; C) fluorescence intensity calculated from flow cytometry data and miRNA intake efficiency based on the flow 
cytometry; B) (*p < 0.05, **p < 0.01); D) RT-PCR analysis of the transfected miR-5160 and the osteogenic differentiation genes (*p < 0.05, **p < 0.01). 
Normalize by the housekeeping gene, GAPDH; E) osteogenic cellular mineralization evaluation (Von Kossa staining) of BMSCs after induction by 
miR-5106 mimics delivered by PEI 25K, LIPO, and RC101.
Figure 1. Structure and properties characterizations of θ-defensin peptides as a miRNA vector. (A) A hypothetical model of the oxidative and reduced 
form of RC101 made by templating its sequence on the backbone of a similar peptide from porcine neutrophils, protegrin-1 (PDB accession code: 
1PG1); (B) CD spectrum of reduced and oxidative RC101, both at 0.5 mg/ml in PBS at pH 7.4; (C, D) Synthesized reduced (C) and oxidative RC101 
(D) were purified by a reverse phase HPLC and their molecular weights were determined by ESIMS; (E) Zeta potentials of reduced RC101 and oxidative 
RC101 measured in PBS at pH 7.4; (F) MiR-5106 loading ability of PEI 25K, reduced RC101 and oxidative RC101 measured by a direct electrophoretic 
retardation analysis; (G) MiR-5106 binding affinity of LIPO, PEI 25K, reduced RC101 and oxidative RC101 measured by a heparin competition experi-
ment; (H) Serum stability evaluation of RC101-miR-5106 complexes; (I) Cytotoxicity test of LIPO, PEI 25K and oxidative RC101. (J) Cytotoxicity analysis 
of RC101-miR-5106 and reduced RC101-miR-5106 complexes.
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In this study, the effectiveness of miR-5106 after transfec-
tion into BMSCs by various complexes was verified through 
investigating the osteoblastic differentiation of BMSCs. After 
transfecting miR-5106 into BMSCs for 2 and 3 weeks, RC101 
group showed a significantly high Sox 9 expression, as com-
pared to PEI 25K, Lipo, and reduced RC101 group (Figure 2D; 
Figure S8B, Supporting Information). In addition, during the 
culture periods of 3 weeks, the osteoblastic genes including 
Runx 2 and Sp 7 were also significantly upregulated in RC101 
group in contrast to PEI 25K, Lipo, and reduced RC101 group 
(Figure 2D; Figure S8C and D, Supporting Information). The 
transfected reduced RC101@miR-5106 could also enhance the 
Runx2 expression in BMSCs after 3 weeks (Figure S9, Sup-
porting Information). The enhanced osteoblastic differentia-
tion of BMSCs by RC101@miR-5106 was further confirmed 
by cellular minerialization staining (Figure 2E). RC101 group 
demonstrated the significantly strong positive staining (black), 
as compared with other groups (Figure 2E; Figures S8 and S10, 
Supporting Information). The significantly high-osteoblastic 
differentiation performance for RC101@miR-5106 group sug-
gested that the miR-5106 could be released efficiently from 
RC101 vector. The RC101 also demonstrated the significant 
antibacterial activity at different concentrations, indicating its 
potential multifunctional applications (Figure S11, Supporting 
Information).
In summary, we have demonstrated a novel synthetic 
θ-defensin peptide, RC101, which possesses several advantages 
as the next generation gene vector: high biocompatibility and 
miRNA loading, good serum stability, strong cellular uptake, 
and transfection efficiency, redox-responsive miRNA controlled 
release in cells. The RC101@miR-5106 is highly effective to 
enhance the osteoblastic differentiation of BMSCs compared 
with commercial transfection reagents PEI 25K and Lipo. Our 
work first presents that the synthetic θ-defensin peptide is an 
excellent candidate for highly efficient miRNAs delivery, and 
may have promising applications in smart gene therapy. This 
study may also provide a new strategy to develop next genera-
tion smart defensin peptide-based gene delivery system, not-
withstanding there exist some potential limitations such as 
DNA transfection and targeting transfection in vivo necessarily 
to be overcome.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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